| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 4960 | 2017 |
| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The lancet oncology 20 (1), 31-42, 2019 | 1951 | 2019 |
| KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma M Wang, J Munoz, A Goy, FL Locke, CA Jacobson, BT Hill, ... New England journal of medicine 382 (14), 1331-1342, 2020 | 1424 | 2020 |
| Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, YI Lin, S Dahiya, ... Journal of Clinical Oncology 38 (27), 3119-3128, 2020 | 616 | 2020 |
| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis AR Mato, C Nabhan, MC Thompson, N Lamanna, DM Brander, B Hill, ... Haematologica 103 (5), 874, 2018 | 422 | 2018 |
| MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies GS Choudhary, S Al-Harbi, S Mazumder, BT Hill, MR Smith, J Bodo, ... Cell death & disease 6 (1), e1593-e1593, 2015 | 375 | 2015 |
| Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ... The Lancet Haematology 7 (7), e511-e522, 2020 | 277 | 2020 |
| Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, ... Annals of Oncology 28 (5), 1050-1056, 2017 | 264 | 2017 |
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience AR Mato, C Nabhan, PM Barr, CS Ujjani, BT Hill, N Lamanna, ... Blood, The Journal of the American Society of Hematology 128 (18), 2199-2205, 2016 | 216 | 2016 |
| Combined content selection and display user interface B Hill, J Satterfield, J Harris, H Bjordahl, M Van Tilburg, J Morse, ... US Patent App. 10/836,154, 2005 | 207 | 2005 |
| Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance I Kapoor, J Bodo, BT Hill, ED Hsi, A Almasan Cell death & disease 11 (11), 941, 2020 | 180 | 2020 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 167 | 2018 |
| Outcomes of patients with double-hit lymphoma who achieve first complete remission DJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ... Journal of Clinical Oncology 35 (20), 2260-2267, 2017 | 166 | 2017 |
| Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study M Wang, J Munoz, A Goy, FL Locke, CA Jacobson, BT Hill, ... Journal of clinical oncology, 2022 | 153 | 2022 |
| Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience LJ Nastoupil, MD Jain, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 132 | 2018 |
| Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma SS Neelapu, CA Jacobson, A Ghobadi, DB Miklos, LJ Lekakis, ... Blood, The Journal of the American Society of Hematology 141 (19), 2307-2315, 2023 | 131 | 2023 |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology WG Wierda, JC Byrd, JS Abramson, SF Bilgrami, G Bociek, D Brander, ... Journal of the National Comprehensive Cancer Network 18 (2), 185-217, 2020 | 130 | 2020 |
| Side-by-side shared calendars B Hill, H Bjordahl US Patent 9,715,678, 2017 | 126 | 2017 |
| Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American … MA Kharfan-Dabaja, A Kumar, M Hamadani, S Stilgenbauer, P Ghia, ... Biology of Blood and Marrow Transplantation 22 (12), 2117-2125, 2016 | 120 | 2016 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 115 | 2020 |
